Eckel Hans E, Bradley Patrick J
Department of Oto-Rhino-Laryngology, Klagenfurt General Hospital, Klagenfurt, Austria,
Department of Otolaryngology, Head and Neck Surgery, Nottingham University Hospital NHS Trust, Queens Medical Centre Campus, Nottingham, United Kingdom.
Adv Otorhinolaryngol. 2019;83:47-53. doi: 10.1159/000492308. Epub 2019 Feb 12.
Patients with hypopharyngeal cancer are difficult to treat because they typically present with advanced disease, poor general health status and severe nutritional problems. Currently, treatment options for previously untreated and newly diagnosed hypopharyngeal cancer patients include surgery of the primary tumour and lymph nodes metastasis, radiotherapy, systemic medical treatment, including traditional chemotherapy and immunotherapy. Currently, a multimodal treatment approach is preferred using surgery, radiotherapy and systemic therapy with curative intent and best supportive care in patients considered unfit for curative treatment or patients presenting with distant metastatic spread. More detailed topics regarding the choice of treatment include biological and immunological host factors and their use for defining individualised cancer care, integration of novel therapies, integration of patient autonomy into clinical reasoning and dealing with patients' trade-offs between oncological outcome and individual quality of life, local availability of diagnostic therapeutic procedures and volume-outcome relationships for head and neck cancer surgery, radiotherapy and specialised supportive care. They also include considerations regarding potential delay between diagnosis and treatment, and between different treatment modalities within the frame of multimodal therapy. To date only one randomised trial comparing surgical versus non-surgical approaches has been published. Most randomised trials dealing with hypopharyngeal cancer compare different chemo- and radiotherapy regimen, but do not compare with a surgical approach. On the other hand, most studies on the results of surgery are best considered to be of low-quality case series. At the same time, many of the chemotherapy and radiation oncology studies in head and neck cancer include patients with different primary sites, where hypopharyngeal cancer patients when included usually account for a minority of the study population. Therefore, choosing the best treatment for an individual patient with hypopharyngeal cancer relies on personal experience and local expertise of the multidisciplinary team involved in the therapeutic process.
下咽癌患者难以治疗,因为他们通常表现为疾病进展、总体健康状况差和严重的营养问题。目前,既往未接受治疗且新诊断的下咽癌患者的治疗选择包括原发性肿瘤和淋巴结转移灶的手术、放疗、全身药物治疗,包括传统化疗和免疫治疗。目前,对于不适合进行根治性治疗或出现远处转移扩散的患者,多模式治疗方法更受青睐,即采用具有治愈意图的手术、放疗和全身治疗以及最佳支持治疗。关于治疗选择的更详细主题包括生物学和免疫学宿主因素及其在确定个体化癌症治疗中的应用、新疗法的整合、将患者自主权纳入临床推理以及处理患者在肿瘤学结果和个人生活质量之间的权衡、诊断治疗程序的当地可及性以及头颈癌手术、放疗和专科支持治疗的手术量-疗效关系。它们还包括关于诊断与治疗之间以及多模式治疗框架内不同治疗方式之间潜在延迟的考虑。迄今为止,仅发表了一项比较手术与非手术方法的随机试验。大多数涉及下咽癌的随机试验比较了不同的化疗和放疗方案,但未与手术方法进行比较。另一方面,大多数关于手术结果的研究最好被视为低质量的病例系列。同时,许多头颈癌的化疗和放射肿瘤学研究纳入了不同原发部位的患者,其中下咽癌患者在纳入时通常占研究人群的少数。因此,为个体下咽癌患者选择最佳治疗方案依赖于参与治疗过程的多学科团队的个人经验和当地专业知识。